Mesenchymal stem cell therapy: Two steps forward, one step back

被引:479
作者
Ankrum, James [1 ]
Karp, Jeffrey M. [1 ]
机构
[1] Harvard Univ, Sch Med,Harvard MIT Div Hlth Sci & Technol, Brigham & Womens Hosp, Dept Med,Harvard Stem Cell Inst, Cambridge, MA 02139 USA
关键词
BONE-MARROW; STROMAL CELLS; MYOCARDIAL-INFARCTION; CARDIAC-FUNCTION; STEM/PROGENITOR CELLS; TRAFFICKING; REPAIR; MICE; MSCS; LUNG;
D O I
10.1016/j.molmed.2010.02.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mesenchymal stem cell (MSC) therapy is poised to establish a new clinical paradigm; however, recent trials have produced mixed results. Although MSC were originally considered to treat connective tissue defects, preclinical studies revealed potent immunomodulatory properties that prompted the use of MSC to treat numerous inflammatory conditions. Unfortunately, although clinical trials have met safety endpoints, efficacy has riot been demonstrated. We believe the challenge to demonstrate efficacy can be attributed in part to an incomplete understanding of the fate of MSC following infusion. Here, we highlight the clinical status of MSC therapy and discuss the importance of cell-tracking techniques, which have advanced our understanding of the fate and function of systemically infused MSC and might improve clinical application.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 53 条
[1]   Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium - Feasibility, cell migration, and body distribution [J].
Barbash, IM ;
Chouraqui, P ;
Baron, J ;
Feinberg, MS ;
Etzion, S ;
Tessone, A ;
Miller, L ;
Guetta, E ;
Zipori, D ;
Kedes, LH ;
Kloner, RA ;
Leor, J .
CIRCULATION, 2003, 108 (07) :863-868
[2]   Mesenchymal stem cells: Revisiting history, concepts, and assays [J].
Bianco, Paolo ;
Robey, Pamela Gehron ;
Simmons, Paul J. .
CELL STEM CELL, 2008, 2 (04) :313-319
[3]   Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis [J].
Burchfield, Jana S. ;
Dimmeler, Stefanie .
FIBROGENESIS & TISSUE REPAIR, 2008, 1
[4]   Why are MSCs therapeutic? New data: new insight [J].
Caplan, Al .
JOURNAL OF PATHOLOGY, 2009, 217 (02) :318-324
[5]  
Chen SF, 2004, CHINESE MED J-PEKING, V117, P1443
[6]   Bone marrow cell trafficking following intravenous administration [J].
Cui, JS ;
Wahl, RL ;
Shen, TL ;
Fisher, SJ ;
Recker, E ;
Ginsburg, D ;
Long, MW .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (04) :895-902
[7]   Mesenchymal stem cells reside in virtually all post-natal organs and tissues [J].
da Silva Meirelles, Lindolfo ;
Chagastelles, Pedro Cesar ;
Nardi, Nance Beyer .
JOURNAL OF CELL SCIENCE, 2006, 119 (11) :2204-2213
[8]   Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli [J].
Di Nicola, M ;
Carlo-Stella, C ;
Magni, M ;
Milanesi, M ;
Longoni, PD ;
Matteucci, P ;
Grisanti, S ;
Gianni, AM .
BLOOD, 2002, 99 (10) :3838-3843
[9]   Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement [J].
Dominici, M. ;
Le Blanc, K. ;
Mueller, I. ;
Slaper-Cortenbach, I. ;
Marini, F. C. ;
Krause, D. S. ;
Deans, R. J. ;
Keating, A. ;
Prockop, D. J. ;
Horwitz, E. M. .
CYTOTHERAPY, 2006, 8 (04) :315-317
[10]  
FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267